The Oncology Journal Club Episode 13: ESMO Special 1

Google+ Pinterest LinkedIn Tumblr +

Today’s episode of The Oncology Journal Club is the first of our ESMO Special Episodes featuring Supportive Care, GI Cancers and much more…

This week we are back after a short break whilst the team enjoyed a fantastic virtual ESMO – today’s episode is the first of three special ESMO editions.

In the first episode the team select papers that caught their eye from a wide range of specialty areas, we chat to Lizzy Smyth about the practice changing GI presentations and Hans give us his thoughts on Supportive Care. We also have some controversial questions from a very special international contributor, a true cult figure in the oncology world, so you are in for a entertaining and informative episode.

Next week’s Special ESMO Episode will feature Ben Solomon discussing Lung Cancer, Maria Bourlon on GU highlights and Phillippe Aftimos on Phase 1 trials so watch out for this one.

With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club.


About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

Today’s episode is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.


This Week’s Papers:

Supportive Care Papers:

  1. Krzyzanowska, M.K., et al. A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  2. Nunez Abad, M., et al. Impact of malnutrition according to the GLIM criteria in cancer patients admitted to hospital. Annals of Oncology (2020) 31 (suppl_4): S988-S1017. 10.1016/annonc/annonc291. Access online here.
  3. Dizdar, O., et al. Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer. Annals of Oncology (2020) 31 (suppl_4): S874-S880. 10.1016/annonc/annonc264. Access online here.

Main Papers:

  1. Lepage1, C., et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) – PRODIGE 13 a FFCD phase III trial. Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270. Access online here.
  2. Shi, M., et al. Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase III trial. Annals of Oncology (2020) 31 (suppl_4): S629-S644. 10.1016/annonc/annonc278. Access online here.
  3. Renouf, D.J., et al. The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  4. Blay, J., et al. High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study. Annals of Oncology (2020) 31 (suppl_4): S914-S933. 10.1016/annonc/annonc288. Access online here.
  5. Toulmonde, M., et al. TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  6. Cohen, E.E., et al. Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Annals of Oncology (2020) 31 (suppl_4): S599-S628. 10.1016/annonc/annonc277. Access online here.
  7. Tao, Y., et al. Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  8. Zuur, L., et al. Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  9. Banerjee, S., et al. The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  10. Steindl, A., et al. Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020. Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269. Access online here.
  11. John, T., et al. Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269. Access online here.
  12. Q&A and Discussion: Proffered Paper – NETs. Chaired by Eva Segelov. Access online here.
  13. Capdevila, J., et al. A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology (2020) 31 (suppl_4): S711-S724. 10.1016/annonc/annonc281. Access online here.
  14. Vaishampayan, U.N., et al. ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1). Annals of Oncology (2020) 31 (suppl_4): S645-S671. 10.1016/annonc/annonc279. Access online here. (Investor Update)
  15. Dyba, T.A., et al. Estimation of European cancer burden for the year 2020. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  16. Necchi, A., et al. Association between human papillomavirus (HPV) infection and outcome of perioperative nodal radiotherapy for penile carcinoma.Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274. Access online here.
  17. Monkhorst, K., et al. Validation of whole genome sequencing in routine clinical practice. Annals of Oncology (2020) 31 (suppl_4): S725-S734. 10.1016/annonc/annonc262. Access online here.

GI Papers from Lizzy’s Presentation

  1. Moehler, M., et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  2. Boku, N., et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  3. Kato, K., et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  4. Kelly, R.J., et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
  5. André, T., et al. Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study. Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270. Access online here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

 

 

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Lizzy Smyth

Elizabeth (Lizzy) Smyth is an consultant in gastrointestinal oncology at Addenbrooke’s Hospital in Cambridge. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded an Irish Society of Medical Oncology fellowship to train at Memorial Sloan-Kettering Centre, New York. Following this she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer and she has worked on trial design and management of national and international trials. She is a member of the European Society of Medical Oncology Faculty GI educational faculty and in 2017 was elected as secretary of the EORTC GI clinical trials group for the period 2018-2021. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Lizzy Smyth, our Special Guest Interviewer and Graham Knowles.

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.